NeoTX Overview
NeoTX is leveraging its proprietary Selective T cell Redirection (STR) platform to develop new targeted anticancer immunotherapies. STR binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating immune cells away from the suppressive tumor environment to mount an effective antibacterial response. The technology effectively converts a weak immune response against the tumor to a powerful yet safe native antibacterial immune reaction. The company's lead STR molecule, Naptumomab estafenatox, is currently in clinical development for advanced solid tumors.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Curing cancer is no small feat: Israel's NeoTX is still up for the challenge
Israeli startup NeoTX, a biopharmaceutical company focused on oncology research and development, is using its Tumor Targeted Superantigen (TTS) platform technology to coat tumors with a superantigen and activate the bodys immune system to attack cancer cells. The TTS technology has the potential to challenge the effectiveness of other cancer treatments. NeoTXs CEO, Asher Nathan, discussed the companys unique approach to oncology and its goal of becoming a leading company for oncology treatment. The company, founded in 2015, has raised over $80 million and is headquartered in Rehovot, Israel.
Expand
growth-positive
NeoTX announces successful first stage completion of its Phase 2a clinical trial of naptumomab estafenatox (NAP), in combination with docetaxel in advanced non-small cell lung cancer (NSCLC)
NeoTX Therapeutics has successfully completed the first stage of a clinical trial for its drug naptumomab estafenatox in combination with docetaxel for advanced non-small cell lung cancer patients. The trial showed promising results, providing new treatment options for patients. Additionally, NeoTX recently completed the acquisition of InterX, a computer-aided drug discovery company, which strengthens its drug discovery capabilities. NeoTX plans to investigate the combination of naptumomab estafenatox with checkpoint inhibitors in various indications. NeoTX is a vertically integrated clinical-stage immuno-oncology drug development company utilizing its proprietary Tumor Targeted Superantigen platform.
PartnersAcquisition
growth-positive
NEOTX ACQUIRES INTERX, ADDS WORLD CLASS DISCOVERY ARM
NeoTX has announced the acquisition of InterX, a drug discovery company utilizing advanced proprietary tools for the discovery and design of therapeutic molecules. This acquisition expands NeoTXs capabilities and comes with a pipeline of early drugs. The technologies acquired have the potential to increase the speed of drug discovery and save time in the typical drug discovery timeline. NeoTX aims to advance best-in-class drug candidates and increase the value of its pipeline. The Chief Scientist of NeoTX and co-founder of InterX, Nobel Prize Laureate Prof. Roger Kornberg, has assumed the role of Chairman of the Board of NeoTX.
Acquisition
growth-positive
NeoTX Therapeutics promotes Marcel Rozencweig, M.D., to President and welcomes Scott Z. Fields, M.D., as new Chief Medical Officer
NeoTX Therapeutics has announced the promotion of Marcel Rozencweig to President and the appointment of Scott Z. Fields as the new chief medical officer. Rozencweig, the current CMO, will help accelerate growth and expand strategic industry partnerships, while Fields brings over 30 years of experience in clinical drug development. The company is delighted with the new additions to its leadership team and believes their expertise will be valuable for clinical development and registration strategies. NeoTX is a clinical-stage immuno-oncology company developing targeted anticancer immunotherapies.
Management Changes
growth-positive
NeoTX to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium
NeoTX Therapeutics will participate in the LifeSci Partners Private Company Virtual Summer Symposium to deliver a corporate update to potential investors and strategic partners. The presentation will cover recent and upcoming milestones, as well as the clinical progress of their lead candidate in a Phase 1b clinical trial for the treatment of advanced and metastatic solid tumors. The lead candidate is being evaluated in combination with AstraZenecas checkpoint inhibitor. The symposium will feature presentations from over 130 private healthcare companies and panel discussions with industry leaders and investment communities.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $65.5M |
| Last funding | $45M |
| Stage | C |
| Rounds | 4 |
| Investors | 5 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | neotx.com/ |
| Careers | Careers page |
Locations
Prof. Haim Pekeris Street 2, Rehovot, Israel
Photos & Videos
3 item(s)
